Daewoong Pharmaceutical

Daewoong Pharmaceutical, founded in 1945, is a prominent South Korean pharmaceutical entity listed on the KRX under the ticker 069620. The company specializes in the development, manufacturing, and commercialization of diverse pharmaceutical products and healthcare solutions. By maintaining a robust in-house research and development infrastructure, the firm ensures high-quality production standards that meet international cGMP requirements. Daewoong Pharmaceutical serves as a critical player in the global healthcare market, focusing on delivering comprehensive medical solutions to a wide range of international customers.

Operating with a workforce of 1,000-5,000 employees, the company maintains a significant operational footprint across two primary locations. Meet Daewoong Pharmaceutical's team to understand the organizational structure and leadership driving these expansive operations. The firm leverages advanced enterprise resource planning systems, including SAP ERP, to streamline its manufacturing and supply chain processes. This technical integration supports the company's ability to manage complex pharmaceutical formulations, including injections, biologicals, and liquid suspensions, ensuring consistent quality control across its global distribution network.

With an annual revenue of approximately $1.0B, Daewoong Pharmaceutical continues to expand its international presence by establishing strategic branch offices and research centers throughout Asia and the United States. The company’s commitment to innovation is reflected in its diverse product portfolio, which ranges from specialized pharmaceutical formulations to comprehensive healthcare services. By prioritizing R&D and maintaining rigorous quality standards, the organization aims to solidify its position as a leading global healthcare provider.